DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
5 financial gifts for a Happy Mother's Day — take a look !
11/05/2025
FPIs continue to invest ; inject Rs 14,167 cr in equities in May
11/05/2025
Eight of top-10 most-valued firms saw combined Rs 1.60 lakh cr erosion in mkt valuation last week
11/05/2025
Berlin says situation in Gaza 'unbearable', calls for ceasefire : minister
10/05/2025
As US, China begin trade talks in Geneva, Trump's tariff hammer looks less mighty than he claims
10/05/2025
How US-China tariffs reached sky-high levels in 3 months
10/05/2025
